AVRO RSI Chart
Last 7 days
-1.5%
Last 30 days
-0.8%
Last 90 days
-5.2%
Trailing 12 Months
10.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 2.4M |
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 719.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 05, 2024 | golipour azadeh | sold (taxes) | -14,698 | 1.2016 | -12,232 | chief technology officer |
Feb 05, 2024 | avruch steven | sold (taxes) | -12,996 | 1.202 | -10,812 | chief legal officer |
Feb 05, 2024 | ridha essra | sold (taxes) | -20,353 | 1.2006 | -16,953 | chief medical officer |
Feb 05, 2024 | ostrowski erik | sold (taxes) | -15,745 | 1.202 | -13,099 | interim ceo, president and cfo |
Feb 01, 2024 | avruch steven | acquired | - | - | 32,834 | chief legal officer |
Feb 01, 2024 | ostrowski erik | acquired | - | - | 40,084 | interim ceo, president and cfo |
Feb 01, 2024 | ridha essra | acquired | - | - | 32,834 | chief medical officer |
Feb 01, 2024 | golipour azadeh | acquired | - | - | 37,334 | chief technology officer |
Jun 12, 2023 | golipour azadeh | sold (taxes) | -6,634 | 1.1903 | -5,574 | chief technology officer |
Jan 24, 2023 | mackay geoffrey | acquired | 41,859 | 0.91 | 45,999 | president & ceo |
Which funds bought or sold AVRO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.71 | -246,749 | 2,178,500 | -% |
Feb 26, 2024 | Virtu Financial LLC | reduced | -71.97 | -41,000 | 14,000 | -% |
Feb 15, 2024 | BARCLAYS PLC | unchanged | - | -3,000 | 24,000 | -% |
Feb 14, 2024 | BOOTHBAY FUND MANAGEMENT, LLC | unchanged | - | -27,870 | 210,573 | -% |
Feb 14, 2024 | TWO SIGMA ADVISERS, LP | added | 12.05 | -3,828 | 360,536 | -% |
Feb 14, 2024 | MILLENNIUM MANAGEMENT LLC | sold off | -100 | -55,243 | - | -% |
Feb 14, 2024 | TANG CAPITAL MANAGEMENT LLC | sold off | -100 | -5,409,540 | - | -% |
Feb 14, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -5.61 | -84,047 | 420,942 | -% |
Feb 14, 2024 | BNP PARIBAS FINANCIAL MARKETS | unchanged | - | -539 | 4,072 | -% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | added | 62.81 | 99,386 | 326,382 | 0.01% |
Unveiling Avrobio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Avrobio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Avrobio Inc News
Income Statement (Quarterly) | ||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q3 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | -10.4% | 1,260 | 1,407 | 248 | 180 | 111 | 2.00 | 9.00 | - | - |
Operating Expenses | -54.4% | 9,627 | 21,091 | 25,220 | 25,257 | 22,985 | 32,620 | 31,375 | 26,884 | 28,064 |
S&GA Expenses | -16.4% | 5,237 | 6,262 | 7,887 | 7,120 | 7,066 | 9,577 | 8,831 | 8,357 | 8,477 |
R&D Expenses | -70.4% | 4,390 | 14,829 | 17,333 | 18,137 | 15,919 | 23,043 | 22,544 | 18,527 | 19,587 |
Interest Expenses | - | - | - | 463 | 423 | 374 | - | - | - | - |
Net Income | 59.3% | -8,785 | -21,577 | -24,957 | -25,034 | -22,969 | -32,613 | -31,387 | -26,899 | -28,131 |
Net Income Margin | - | 5.02* | - | -140.49* | -147.27* | -151.71* | -165.55* | -171.34* | -167.79* | -166.50* |
Free Cashflow | 60.3% | -8,031 | -20,223 | -20,292 | -23,673 | -16,501 | -25,091 | -21,194 | -27,454 | -30,569 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -8.5% | 101 | 111 | 134 | 83.00 | 104 | 129 | 146 | 175 | 204 | 216 | 238 | 246 | 271 | 233 | 256 | 270 | 201 | 217 | 102 | 117 | 133 |
Current Assets | -8.2% | 100 | 109 | 129 | 77.00 | 100 | 126 | 142 | 171 | 199 | 212 | 234 | 242 | 267 | 229 | 251 | 265 | 196 | 214 | 98.00 | 114 | 130 |
Cash Equivalents | -6.7% | 99.00 | 106 | 125 | 72.00 | 93.00 | 116 | 132 | 162 | 190 | 201 | 226 | 233 | 260 | 220 | 244 | 258 | 188 | 206 | 90.00 | 108 | 127 |
Net PPE | - | - | - | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Liabilities | -17.1% | 6.00 | 8.00 | 12.00 | 30.00 | 29.00 | 31.00 | 28.00 | 32.00 | 34.00 | 23.00 | 17.00 | 13.00 | 17.00 | 25.00 | 16.00 | 13.00 | 15.00 | 10.00 | 9.00 | 11.00 | 11.00 |
Current Liabilities | -15.9% | 6.00 | 8.00 | 12.00 | 14.00 | 13.00 | 16.00 | 13.00 | 17.00 | 19.00 | 23.00 | 17.00 | 13.00 | 17.00 | 25.00 | 15.00 | 13.00 | 14.00 | 10.00 | 9.00 | 10.00 | 11.00 |
Shareholder's Equity | -7.9% | 95.00 | 103 | 122 | 53.00 | 75.00 | 98.00 | 118 | 143 | 169 | 194 | 221 | 233 | 254 | 208 | 240 | 257 | 186 | 207 | 93.00 | 107 | 122 |
Retained Earnings | -1.9% | -477 | -468 | -446 | -514 | -489 | -464 | -441 | -413 | -383 | -355 | -322 | -291 | -264 | -236 | -199 | -170 | -144 | -122 | -104 | -88.84 | -71.74 |
Additional Paid-In Capital | 0.1% | 572 | 571 | 569 | 567 | 565 | 562 | 560 | 557 | 553 | 549 | 544 | 524 | 519 | 444 | 439 | 427 | 331 | 329 | 198 | 196 | 194 |
Shares Outstanding | 0.2% | 45.00 | 45.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 42.00 | 44.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 34,838 | - | - | - | 337 | - | - | - | 534 | - | - | - | 289 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 60.3% | -8,031 | -20,223 | -14,652 | -20,284 | -23,673 | -16,415 | -29,106 | -28,014 | -25,897 | -24,824 | -19,965 | -27,339 | -30,488 | -24,863 | -21,018 | -22,434 | -18,583 | -13,382 | -17,965 | -17,738 | -11,434 |
Share Based Compensation | -72.7% | 607 | 2,220 | 1,534 | 2,530 | 2,255 | 2,656 | 3,233 | 3,378 | 4,085 | 5,168 | 4,691 | 4,635 | 4,102 | 4,805 | 3,899 | 2,822 | 1,885 | 1,797 | 1,663 | 1,455 | 1,079 |
Cashflow From Investing | -87.5% | 150 | 1,198 | 83,736 | -8.00 | - | -86.00 | -149 | -32.00 | -850 | -267 | -1,229 | -115 | -81.00 | -31.00 | -488 | -577 | -766 | -78.00 | -401 | -340 | -234 |
Cashflow From Financing | -66.9% | 59.00 | 178 | -16,321 | 55.00 | 59.00 | 60.00 | 1.00 | 142 | 14,945 | 22.00 | 14,605 | 799 | 70,705 | 60.00 | 8,191 | 93,663 | 30.00 | 129,474 | 238 | 252 | -139 |
Consolidated Statements Of Operations And Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 47,700 | $ 72,186 |
General and administrative | 23,967 | 33,248 |
Total operating expenses | 71,667 | 105,434 |
Gain on asset sale | 83,736 | 0 |
Loss on impairment | (1,877) | 0 |
Income (loss) from operations | 10,192 | (105,434) |
Other income (expense): | ||
Interest income (expense), net | 2,420 | (299) |
Other expense, net | (78) | (157) |
Total other income (expense), net | 2,342 | (456) |
Income (loss) before income taxes | 12,534 | (105,890) |
Provision for income tax expense | 377 | 0 |
Net income (loss) and comprehensive income (loss) attributable to common stockholders-basic and diluted | $ 12,157 | $ (105,890) |
Net income (loss) per share applicable to common stockholders-basic | $ 0.27 | $ (2.42) |
Net income (loss) per share applicable to common stockholders-diluted | $ 0.27 | $ (2.42) |
Weighted-average common shares outstanding-basic | 44,327 | 43,739 |
Weighted-average common shares outstanding-diluted | 44,568 | 43,739 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 98,020 | $ 92,563 |
Restricted cash | 283 | 283 |
Prepaid expenses and other current assets | 1,958 | 7,112 |
Total current assets | 100,261 | 99,958 |
Operating lease assets | 432 | 1,057 |
Property and equipment, net | 0 | 2,894 |
Restricted cash, net of current portion | 400 | 0 |
Other assets | 0 | 40 |
Total assets | 101,093 | 103,949 |
Current liabilities: | ||
Accounts payable | 27 | 384 |
Accrued expenses and other current liabilities | 5,449 | 11,732 |
Operating lease liabilities | 878 | 999 |
Total current liabilities | 6,354 | 13,115 |
Note payable, net of discount | 0 | 15,276 |
Operating lease liabilities, net of current portion | 0 | 188 |
Total liabilities | 6,354 | 28,579 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 10,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.0001 par value; 150,000 shares authorized as of December 31, 2023 and 2022; 44,654 and 43,916 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 4 | 4 |
Additional paid-in capital | 572,010 | 564,798 |
Accumulated deficit | (477,275) | (489,432) |
Total stockholders’ equity | 94,739 | 75,370 |
Total liabilities and stockholders' equity | $ 101,093 | $ 103,949 |
 | www.avrobio.com |
---|---|
 | 78 |